ASCO 2021: what should you look out for?

In this piece we highlight the key news headlines released from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (4−8 June 2021). IMpower010: Tecentriq® improves disease-free survival for some early lung cancer patients Interim data from the IMpower010 Phase III clinical trial has demonstrated that Tecentriq (atezolizumab) following surgery and chemotherapy reduces the risk of disease-free survival by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50-0.88) in patients with Stage II-IIIA NSCLC, whose tumors express PD-L1 ≥1%, compared with best supportive care. The data is pivotal as it is the first time that cancer immunotherapy has brought a clinically...